Maximizing Treatment Benefits for our Patients with Retinal Vascular Diseases
Chairperson(s): J. Kitchens USA
Speakers and presentations:
V. Chaudhary CANADA
11:00 Maximizing vision outcomes in DME: is baseline VA only one piece of the puzzle?
J. Garweg SWITZERLAND
11:10 Durability that lasts: proactive, extended dosing in retinal vascular disease
A. Chang AUSTRALIA
11:20 Aflibercept in the real-world: what’s the bigger picture?
T. Langmann GERMANY
11:27 Understanding the target: what are we aiming for?
11:35 End of Session